GeneCentric to present data on the Purity Independent Subtyping of Tumor (PurIST) Test at AACR Pancreatic Conference (GeneCentric Therap Press Release)
"GeneCentric Therapeutic...announced today the poster presentation of further clinical validation data for PurISTSM, a novel RNA-expression test, in collaboration with Tempus. PurIST identifies patients with the classical subtype of pancreatic ductal adenocarcinoma (PDAC) that are likely to experience longer overall survival (OS) with standard of care (SOC) FOLFIRINOX than patients with the basal subtype of PDAC. The presentation will be made at the 8th AACR Special Conference on Pancreatic Cancer in Boston, Massachusetts, which runs from September 13-16, 2022."